1. Home
  2. GOF vs EVO Comparison

GOF vs EVO Comparison

Compare GOF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GOF
  • EVO
  • Stock Information
  • Founded
  • GOF 2006
  • EVO 1993
  • Country
  • GOF United States
  • EVO Germany
  • Employees
  • GOF N/A
  • EVO N/A
  • Industry
  • GOF Finance/Investors Services
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GOF Finance
  • EVO Health Care
  • Exchange
  • GOF Nasdaq
  • EVO Nasdaq
  • Market Cap
  • GOF 2.4B
  • EVO 1.5B
  • IPO Year
  • GOF N/A
  • EVO 2021
  • Fundamental
  • Price
  • GOF $14.88
  • EVO $4.21
  • Analyst Decision
  • GOF
  • EVO Buy
  • Analyst Count
  • GOF 0
  • EVO 2
  • Target Price
  • GOF N/A
  • EVO $5.90
  • AVG Volume (30 Days)
  • GOF 789.2K
  • EVO 112.1K
  • Earning Date
  • GOF 01-01-0001
  • EVO 08-13-2025
  • Dividend Yield
  • GOF 15.42%
  • EVO N/A
  • EPS Growth
  • GOF N/A
  • EVO N/A
  • EPS
  • GOF N/A
  • EVO N/A
  • Revenue
  • GOF N/A
  • EVO $851,944,444.00
  • Revenue This Year
  • GOF N/A
  • EVO $10.08
  • Revenue Next Year
  • GOF N/A
  • EVO $10.99
  • P/E Ratio
  • GOF N/A
  • EVO N/A
  • Revenue Growth
  • GOF N/A
  • EVO 1.50
  • 52 Week Low
  • GOF $10.96
  • EVO $2.84
  • 52 Week High
  • GOF $16.76
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • GOF 56.04
  • EVO 54.31
  • Support Level
  • GOF $14.50
  • EVO $3.73
  • Resistance Level
  • GOF $14.66
  • EVO $4.29
  • Average True Range (ATR)
  • GOF 0.12
  • EVO 0.11
  • MACD
  • GOF 0.00
  • EVO 0.01
  • Stochastic Oscillator
  • GOF 68.75
  • EVO 67.61

About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest

Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: